With a market capitalization (market cap) of $1.28B — a measure of how much the company is worth — Vor Biopharma Inc. is the 2404th most valuable company in Healthcare as of August 10, 2026. Shares trade at $23.67, down +0.13% on the day.
of 2,573
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Visit websiteAs of August 10, 2026, Vor Biopharma Inc. (VOR) is worth $1.28B — this is its market capitalization, the total value of all its outstanding shares.
Vor Biopharma Inc.’s market cap is $1.28B, which ranks it #2404 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Vor Biopharma Inc. (VOR) shares trade at $23.67, down 0.13% on the day, as of August 10, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025